Cargando…
Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab
Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612813/ https://www.ncbi.nlm.nih.gov/pubmed/34887178 http://dx.doi.org/10.1016/j.jiac.2021.11.018 |
_version_ | 1784603522624389120 |
---|---|
author | Horiuchi, Hiroshi Sasaki, Hiroaki Miyazaki, Kazuhito Miyata, Nobuyuki Yoshimura, Yukihiro Tachikawa, Natsuo |
author_facet | Horiuchi, Hiroshi Sasaki, Hiroaki Miyazaki, Kazuhito Miyata, Nobuyuki Yoshimura, Yukihiro Tachikawa, Natsuo |
author_sort | Horiuchi, Hiroshi |
collection | PubMed |
description | Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome. |
format | Online Article Text |
id | pubmed-8612813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86128132021-11-26 Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab Horiuchi, Hiroshi Sasaki, Hiroaki Miyazaki, Kazuhito Miyata, Nobuyuki Yoshimura, Yukihiro Tachikawa, Natsuo J Infect Chemother Case Report Lymphoma has been reported to worsen the prognosis of COVID-19 partly because it disturbs the normal production of antibodies. We treated a man with mantle cell lymphoma treated with rituximab, who developed severe COVID-19 with viral shedding that lasted for 78 days. He stayed in the intensive care unit for 28 days and did not respond to any treatment against COVID-19. His increased oxygen demand at rest eventually resolved despite the absence of anti-SARS-CoV-2-IgG. This case illustrates that recovery from COVID-19 can occur without antibody production, and that even patients with an inability to produce antibodies can recover from severe COVID-19. It also illustrates that lymphoma patients who develop severe COVID-19 while on rituximab therapy can recover from a prolonged viral shedding state if the acute lung injury can be overcome. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-02 2021-11-25 /pmc/articles/PMC8612813/ /pubmed/34887178 http://dx.doi.org/10.1016/j.jiac.2021.11.018 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Case Report Horiuchi, Hiroshi Sasaki, Hiroaki Miyazaki, Kazuhito Miyata, Nobuyuki Yoshimura, Yukihiro Tachikawa, Natsuo Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title_full | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title_fullStr | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title_full_unstemmed | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title_short | Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
title_sort | recovery from severe persistent covid-19 without evidence of an anti-sars-cov-2 antibody response in a man with mantle cell lymphoma treated with rituximab |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612813/ https://www.ncbi.nlm.nih.gov/pubmed/34887178 http://dx.doi.org/10.1016/j.jiac.2021.11.018 |
work_keys_str_mv | AT horiuchihiroshi recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab AT sasakihiroaki recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab AT miyazakikazuhito recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab AT miyatanobuyuki recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab AT yoshimurayukihiro recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab AT tachikawanatsuo recoveryfromseverepersistentcovid19withoutevidenceofanantisarscov2antibodyresponseinamanwithmantlecelllymphomatreatedwithrituximab |